Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2020

03.04.2020 | Epidemiology

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors

verfasst von: Maria Alice Franzoi, Caroline Vandeputte, Daniel Eiger, Rafael Caparica, Mariana Brandão, Claudia De Angelis, Alain Hendlisz, Ahmad Awada, Martine Piccart, Evandro de Azambuja

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Body composition parameters including muscle and adipose tissue measurements have emerged as prognostic factors in cancer patients. Besides cell cycle regulation, CDK 4 and 6 also control metabolic processes (lipid synthesis, glycolysis, and mitochondrial function). We studied the impact of baseline body composition parameters on response to CDK 4/6 inhibition and changes on body composition during treatment.

Methods

Retrospective study of 50 patients treated at Institut Jules Bordet between December 2016 and August 2019 with endocrine therapy and CDK 4/6 inhibitor as first or second-line treatment for metastatic breast cancer (BC). CT-based body composition analysis was performed at 3 time points. Cox regression and Kaplan–Meier method were used for the association with Progression-free survival (PFS). Changes in body composition parameters were described in means and compared using paired sampled T test.

Results

Baseline sarcopenia was present in 40% of patients and associated with a significantly worse PFS compared to patients without sarcopenia (20.8 vs 9.6 months, HR 2.52; 95% CI 1.02–6.19, p = 0.037). Patients with higher visceral fat index and higher visceral fat density had better PFS (20.8 vs 10.4 months, HR 0.40; 95% CI 0.16–0.99 p = 0.041-stratified for treatment line). No significant alterations in body composition parameters during treatment were observed.

Conclusion

Sarcopenia is a potential early marker of poor prognosis among patients with metastatic BC treated with CDK 4/6 inhibitors. CT scan evaluation of sarcopenia and adiposity revealed significant prognostic information. Visceral fat could also play an important role in response to CDK 4/6 inhibitors, deserving further investigation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Trestini I, Carbognin L, Monteverdi S et al (2018) Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Crit Rev Oncol Hematol 129:54–66CrossRef Trestini I, Carbognin L, Monteverdi S et al (2018) Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Crit Rev Oncol Hematol 129:54–66CrossRef
2.
Zurück zum Zitat Ligibel JA, Alfano CM, Courneya KS et al (2014) American Society of Clinical Oncology Position Statement on Obesity and Cancer. J Clin Oncol 32:3568–3574CrossRef Ligibel JA, Alfano CM, Courneya KS et al (2014) American Society of Clinical Oncology Position Statement on Obesity and Cancer. J Clin Oncol 32:3568–3574CrossRef
3.
Zurück zum Zitat Cho WK, Choi DH, Park W et al (2018) Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer 18:e1141–e1147CrossRef Cho WK, Choi DH, Park W et al (2018) Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer 18:e1141–e1147CrossRef
4.
Zurück zum Zitat Chan DSM, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914CrossRef Chan DSM, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914CrossRef
5.
Zurück zum Zitat Yerushalmi R, Dong B, Chapman JW et al (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28:1560–1568CrossRef Yerushalmi R, Dong B, Chapman JW et al (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28:1560–1568CrossRef
6.
Zurück zum Zitat Zewenghiel L, Lindman H, Valachis A (2018) Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study. The Breast 40:136–140CrossRef Zewenghiel L, Lindman H, Valachis A (2018) Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study. The Breast 40:136–140CrossRef
7.
Zurück zum Zitat Charette N, Vandeputte C, Ameye L et al (2019) Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. BMC Cancer 19:134CrossRef Charette N, Vandeputte C, Ameye L et al (2019) Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. BMC Cancer 19:134CrossRef
8.
Zurück zum Zitat Greenlee H, Unger JM, LeBlanc M et al (2017) Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev 26:21–29CrossRef Greenlee H, Unger JM, LeBlanc M et al (2017) Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev 26:21–29CrossRef
9.
Zurück zum Zitat Caan BJ, Feliciano EMC, Kroenke CH (2018) The Importance of Body Composition in Explaining the Overweight Paradox in Cancer—Counterpoint. Cancer Res 78:1906–1912CrossRef Caan BJ, Feliciano EMC, Kroenke CH (2018) The Importance of Body Composition in Explaining the Overweight Paradox in Cancer—Counterpoint. Cancer Res 78:1906–1912CrossRef
10.
Zurück zum Zitat Brown JC, Cespedes Feliciano EM, Caan BJ (2018) The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle 9:1200–1208CrossRef Brown JC, Cespedes Feliciano EM, Caan BJ (2018) The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle 9:1200–1208CrossRef
11.
Zurück zum Zitat Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35:3638–3646CrossRef Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35:3638–3646CrossRef
12.
Zurück zum Zitat Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541–1547CrossRef Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541–1547CrossRef
13.
Zurück zum Zitat Rugo HS, Finn RS, Diéras V et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174:719–729CrossRef Rugo HS, Finn RS, Diéras V et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174:719–729CrossRef
14.
Zurück zum Zitat Aguilar V, Fajas L (2010) Cycling through metabolism. EMBO Mol Med 2:338–348CrossRef Aguilar V, Fajas L (2010) Cycling through metabolism. EMBO Mol Med 2:338–348CrossRef
15.
Zurück zum Zitat Lagarrigue S, Lopez-Mejia IC, Denechaud P-D et al (2015) CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation 126:335–348CrossRef Lagarrigue S, Lopez-Mejia IC, Denechaud P-D et al (2015) CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation 126:335–348CrossRef
16.
Zurück zum Zitat Fajas L (2013) Re-thinking cell cycle regulators: the cross-talk with metabolism. Frontiers in Oncology 3:1–6CrossRef Fajas L (2013) Re-thinking cell cycle regulators: the cross-talk with metabolism. Frontiers in Oncology 3:1–6CrossRef
17.
Zurück zum Zitat Hou X, Zhang Y, Li W et al (2018) CDK6 inhibits white to beige fat transition by suppressing RUNX1. Nature Communications 9:1023CrossRef Hou X, Zhang Y, Li W et al (2018) CDK6 inhibits white to beige fat transition by suppressing RUNX1. Nature Communications 9:1023CrossRef
18.
Zurück zum Zitat Iqbal NJ, Lu Z, Liu SM et al (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:e123000CrossRef Iqbal NJ, Lu Z, Liu SM et al (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:e123000CrossRef
19.
Zurück zum Zitat Thibault R, Genton L, Pichard C (2012) Body composition: why, when and for who? Clin Nutr 31:435–447CrossRef Thibault R, Genton L, Pichard C (2012) Body composition: why, when and for who? Clin Nutr 31:435–447CrossRef
20.
Zurück zum Zitat Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006CrossRef Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006CrossRef
21.
Zurück zum Zitat Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol 4:798–804CrossRef Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol 4:798–804CrossRef
22.
Zurück zum Zitat Rier HN, Jager A, Sleijfer S et al (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95–105CrossRef Rier HN, Jager A, Sleijfer S et al (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95–105CrossRef
23.
Zurück zum Zitat Rier HN, Jager A, Sleijfer S et al (2016) The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist 21:1396–1409CrossRef Rier HN, Jager A, Sleijfer S et al (2016) The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist 21:1396–1409CrossRef
24.
Zurück zum Zitat Yip C, Dinkel C, Mahajan A et al (2015) Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 6:489–497CrossRef Yip C, Dinkel C, Mahajan A et al (2015) Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 6:489–497CrossRef
25.
Zurück zum Zitat Kazemi-Bajestani SMR, Mazurak VC, Baracos V (2016) Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 54:2–10CrossRef Kazemi-Bajestani SMR, Mazurak VC, Baracos V (2016) Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 54:2–10CrossRef
26.
Zurück zum Zitat Huang D-D, Wang S-L, Zhuang C-L et al (2015) Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 17:O256–264CrossRef Huang D-D, Wang S-L, Zhuang C-L et al (2015) Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 17:O256–264CrossRef
27.
Zurück zum Zitat Malietzis G, Johns N, Al-Hassi HO et al (2016) Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg 263:320–325CrossRef Malietzis G, Johns N, Al-Hassi HO et al (2016) Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg 263:320–325CrossRef
28.
Zurück zum Zitat Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635CrossRef Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635CrossRef
29.
Zurück zum Zitat Prado CMM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268CrossRef Prado CMM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268CrossRef
30.
Zurück zum Zitat Rossi F, Valdora F, Bignotti B et al (2019) Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review. Cancer Treat Res Commun 21:100154CrossRef Rossi F, Valdora F, Bignotti B et al (2019) Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review. Cancer Treat Res Commun 21:100154CrossRef
31.
Zurück zum Zitat Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6:398–406CrossRef Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6:398–406CrossRef
32.
Zurück zum Zitat Rier HN, Jager A, Sleijfer S et al (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9–15CrossRef Rier HN, Jager A, Sleijfer S et al (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9–15CrossRef
33.
Zurück zum Zitat Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRef Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRef
34.
Zurück zum Zitat Gevorgyan A, Bregni G, Galli G et al (2016) Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. Tumori 102:e11–14CrossRef Gevorgyan A, Bregni G, Galli G et al (2016) Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. Tumori 102:e11–14CrossRef
35.
Zurück zum Zitat Pizzuti L, Natoli C, Gamucci T et al (2017) Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget 8:69025–69037CrossRef Pizzuti L, Natoli C, Gamucci T et al (2017) Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget 8:69025–69037CrossRef
36.
Zurück zum Zitat Ioannides SJ, Barlow PL, Elwood JM et al (2014) Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat 147:237–248CrossRef Ioannides SJ, Barlow PL, Elwood JM et al (2014) Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat 147:237–248CrossRef
37.
Zurück zum Zitat Miard S, Fajas L (2005) Atypical transcriptional regulators and cofactors of PPARgamma. Int J Obes (Lond) 29(Suppl 1):S10–12CrossRef Miard S, Fajas L (2005) Atypical transcriptional regulators and cofactors of PPARgamma. Int J Obes (Lond) 29(Suppl 1):S10–12CrossRef
38.
Zurück zum Zitat Abella A, Dubus P, Malumbres M et al (2005) Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab 2:239–249CrossRef Abella A, Dubus P, Malumbres M et al (2005) Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab 2:239–249CrossRef
39.
Zurück zum Zitat Fielding RA, Vellas B, Evans WJ, et al: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256, 2011 Fielding RA, Vellas B, Evans WJ, et al: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256, 2011
40.
Zurück zum Zitat Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31CrossRef Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31CrossRef
Metadaten
Titel
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors
verfasst von
Maria Alice Franzoi
Caroline Vandeputte
Daniel Eiger
Rafael Caparica
Mariana Brandão
Claudia De Angelis
Alain Hendlisz
Ahmad Awada
Martine Piccart
Evandro de Azambuja
Publikationsdatum
03.04.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05617-2

Weitere Artikel der Ausgabe 1/2020

Breast Cancer Research and Treatment 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.